Small BusinessStrides Arcolab soars on Pfizer deal
Strides Arcolab ended the day at Rs 254, stronger by Rs 19 or 8.2%, on the BSE.
- Strides Arcolab, Pfizer in pact to sell drugs in US - Pfizer to source 40 off-patent cancer care drugs from Strides - TCG Life signs pact with Pfizer - Dr Reddy"s plans to launch Lipitor"s generic version in US - SEC probes 9 deals for insider-trading violations - Shyamal Majumdar: What you pay and why">Shyamal Majumdar: What you pay and why
The stock opened at Rs 245 and touched a new 52-week high of Rs 269 and a low of Rs 245 during the day.
There was a huge surge in volumes, with 8.72 lakh shares being traded on the counter as against the two-week average of 0.65 lakh shares.
Pfizer also had a good day, ending up by Rs 9 or 1% at Rs 951.
------------------------------------------------------------------------------------------------------------------(Updated at 0951 am)
Strides Arcolab has soared on a collaboration with Pfizer, USA. Pfizer will commercialise around 40 off-patent products in the oncology area.
The stock opened at Rs 245 and jumped 14.5% to touch a new 52-week high of Rs 269. It is currently trading with a gain of Rs 24, or 10%, at Rs 259.
The stock has soared 332% from its 52 week low of Rs 60. The counter has seen comparatively hefty trade volumes of 3.82 lakh shares on the BSE, as against the two-week daily average trade of 65,000 shares.
Pfizer is also up 3.2% at Rs 972. The stock opened at Rs 950 and touched a high of Rs 991 - up 5.2% from the previous close. Over 5,719 shares have changed hands on the counter in BSE, as against the two-week daily average trade of 3,206 shares.